E3 ligases

Session Chair - Funded(s)

• MS

  Michael Shaghafi, PhD

  Associate Director
  Frontier Medicines, Inc, California, United States

Session Chair(s)

• 

  Allison Olszewski, PhD

  Senior Director, Lead Discovery
  Triana Biomedicines, Massachusetts, United States

Presentations:

• 10:00 AM – 10:30 AM

  Plexium’s DELPhe platform expedites targeted protein degradation drug discovery
  

  Anastasia Velentza, PhD – Plexium
• 10:30 AM – 11:00 AM

  Discovery and characterization of a VHL molecular glue degrader for cysteine dioxygenase 1
  

  Antonin Tutter, PhD – Novartis Institute for Biomedical Research
• 11:00 AM – 11:30 AM

  Large-scale validation of AlphaLISA SureFire kits to enable target engagement quantification via high-throughput CETSA screening
  

  Benedikt Von Der Heyde, Dr. – Pelago Bioscience AB